Medinol Ltd.
This is a prospective, multi-center, single-arm, open-label, First in Human clinical trial to provide preliminary evidence for the safety and efficacy of the novel IoNIR stent system.
Coronary Stenosis
Coronary Disease
Non-ST Elevated Myocardial Infarction
Cardiovascular Diseases
IoNIR Ridaforolimus-Eluting Coronary Stent System
Not Applicable
Study Type : | Interventional |
Estimated Enrollment : | 60 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | IonMAN Trial-First In Human Study of the IoNIR Ridaforolimus-Eluting Coronary Stent System |
Actual Study Start Date : | August 30, 2022 |
Estimated Primary Completion Date : | December 2023 |
Estimated Study Completion Date : | December 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: IoNIR Ridaforolimus-Eluting Coronary Stent IoNIR Ridaforolimus-Eluting Coronary Stent System |
Device: IoNIR Ridaforolimus-Eluting Coronary Stent System |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
InCor
São Paulo, Brazil,
Recruiting
Meir Medical Center
Kafr Saba, Israel,
Recruiting
Rabin Medical Center
Five pumpkins, Israel,
Recruiting
Sourasky Medical Center
Tel Aviv, Israel,